This led Pfizer to focus on the development of a once-daily version of the drug, which showed early success in Phase I trials (NCT06567327 and NCT06568731)
She was started on letrozole, abemaciclib, and zoledronic acid
Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dub MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM
(2024, Frontiers in Bioengineering and Biotechnology ) reviewed multiple dissolving microneedle systems for anti-obesity molecules and noted the technology's promise for overcoming the permeability barrier that blocks passive transdermal delivery of peptides